Heparin-induced thrombocytopenia is a common and clinically important drug-induced complication that can cause life- and limbthreatening thrombosis. Epidemiologically, the disease has been studied in many different clinical settings, but little is known about it in cancer patients, a population at increased risk for thrombosis and thus exposure to heparin products. Additionally, thrombocytopenia is a common finding in cancer patients. The convergence of these variables highlights the importance of an increased understanding of the disease in cancer patients.
No takes yet. Share an insight, caveat, or question.
Miriovsky et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: